OnePath Diagnostics adopts elea’s AI pathology platform

elea will become the central operating layer for OnePath Diagnostics’ nationwide sub-specialty network, in a rollout that is already underway and expected to finish within weeks. The deal makes OnePath elea’s largest North American customer to date and signals a broader push to put AI into pathology operations, not just diagnostics.

Why it matters: - OnePath Diagnostics will use elea’s Pathology Operating System as the central platform across its nationwide sub-specialty network. - The partnership makes OnePath elea’s largest North American customer to date. - The rollout is designed to speed pathology workflows without forcing pathologists to change the image-management system they already use. - The deal targets one of the most labor-intensive parts of pathology: moving cases from intake through billing with less manual work.

What happened: - elea and OnePath Diagnostics announced a strategic partnership on June 8, 2026. - elea’s software will orchestrate workflow across OnePath’s nationwide network. - The platform will interoperate with the image-management system used by pathologists in the field. - Integration is already underway across OnePath’s central operations. - The companies expect the rollout to complete within the coming weeks.

The details: - elea’s Pathology Operating System runs the lab end-to-end. - The system embeds AI across order intake, accessioning, grossing, staining workflow, reporting and billing. - The platform is designed to accelerate turnaround time. - The software also reduces documentation burden on each case. - Lab leaders get real-time visibility into operations. - OnePath focuses on digital pathology and provides sub-specialty diagnostic expertise to physician groups, laboratories, hospital systems and AI companies. - OnePath built its operation around high-volume workflows and a highly automated lab. - OnePath had been looking for a platform that could scale with growth without disrupting how its pathologists work.

Between the lines: - The partnership suggests elea is positioning its product as infrastructure, not a point tool. - OnePath’s decision to keep pathologists in their existing image-management system points to a low-friction deployment strategy. - The companies are betting that AI can sit inside the operational backbone of pathology while clinical judgment stays with the pathologist. - Sebastian Casu, elea’s co-founder and chief medical officer, said bringing elea live across OnePath’s network will show that AI belongs in the backbone of modern pathology. - Westley J. Bernhardt, OnePath’s managing partner, said the platform offers the integration, usability and intelligence needed to optimize workflows while maintaining diagnostic quality.

What’s next: - OnePath and elea will continue the current integration work across OnePath’s central operations. - The companies expect the nationwide rollout to finish within weeks. - The partnership could serve as a reference point for other large pathology groups evaluating AI-native operating systems.

The bottom line: - elea is moving from software vendor to core operating layer inside a major U.S. pathology network, with OnePath serving as its biggest North American deployment so far.